Prenetics Global Raises IM8 Revenue Guidance, Reports Strong Q1 Growth & $19M Buyback

summarizeSummary

Prenetics Global announced preliminary Q1 2026 results with strong IM8 revenue growth and raised full-year guidance, alongside the execution of a significant portion of its share buyback program.

check_boxKey Events

• Raised Full-Year IM8 Revenue Guidance

  The company increased its full-year 2026 IM8 revenue guidance to $190 million-$210 million, up from the previous range of $180 million-$200 million, reflecting strong brand momentum.

• Strong Q1 2026 Performance

  Prenetics reported preliminary Q1 2026 revenue of $36.0 million, with its IM8 brand revenue growing nearly 6x year-over-year to $33.8 million and 23.1% sequentially from Q4 2025.

• Significant Share Repurchase Execution

  The company repurchased approximately $19 million of its Class A Ordinary Shares through May 13, 2026, representing nearly half of the authorized $40 million share buyback program.

• Robust Cash Position

  Prenetics maintained a strong, debt-free balance sheet with approximately $147 million in combined estimated cash balances, current financial assets, and cash consideration held in escrow as of May 13, 2026.

auto_awesomeAnalysis

Prenetics Global reported preliminary Q1 2026 results showing significant growth in its IM8 brand, which saw nearly 6x year-over-year revenue increase and 23.1% sequential growth. The company raised its full-year IM8 revenue guidance to $190M-$210M and executed $19 million of its share repurchase program, demonstrating strong financial health and confidence in its strategic shift to consumer health.